Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EBITDA: 2009-2024

Historic EBITDA for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to -$13.6 million.

  • Heron Therapeutics' EBITDA fell 264.46% to -$17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.6 million, marking a year-over-year increase of 51.24%. This contributed to the annual value of -$13.6 million for FY2024, which is 87.71% up from last year.
  • Per Heron Therapeutics' latest filing, its EBITDA stood at -$13.6 million for FY2024, which was up 87.71% from -$110.5 million recorded in FY2023.
  • In the past 5 years, Heron Therapeutics' EBITDA ranged from a high of -$13.6 million in FY2024 and a low of -$227.1 million during FY2020.
  • Over the past 3 years, Heron Therapeutics' median EBITDA value was -$110.5 million (recorded in 2023), while the average stood at -$102.0 million.
  • As far as peak fluctuations go, Heron Therapeutics' EBITDA fell by 11.01% in 2020, and later spiked by 87.71% in 2024.
  • Heron Therapeutics' EBITDA (Yearly) stood at -$227.1 million in 2020, then climbed by 2.71% to -$220.9 million in 2021, then rose by 17.61% to -$182.0 million in 2022, then soared by 39.28% to -$110.5 million in 2023, then surged by 87.71% to -$13.6 million in 2024.